# Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)

> **NCT06499025** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **BGI, China** · enrollment: 16 (estimated)

## Conditions studied

- AML
- t(8;21)
- Neoantigen

## Interventions

- **BIOLOGICAL:** targeted AML1-ETO neoantigen cytotoxic T cells (CTL)
- **DRUG:** Cyclophosphamide injection
- **DRUG:** Decitabine Injection
- **DRUG:** Liposome mitoxantrone

## Key facts

- **NCT ID:** NCT06499025
- **Lead sponsor:** BGI, China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-02-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06499025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06499025, "Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06499025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*